Reuters logo
2 months ago
BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30
June 6, 2017 / 6:48 PM / 2 months ago

BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30

June 6 (Reuters) - Agios Pharmaceuticals Inc:

* Updated data from phase 1 trial of oral IDHIFA (enasidenib) demonstrate complete responses and duration of response in patients with relapsed or refractory AML and an IDH2 mutation

* Overall safety profile was consistent with previously reported data for oral IDHIFA​

* IDHIFA NDA has been given a prescription drug user fee act PDUFA action date of Aug. 30, 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below